发明名称 DOSING REGIMEN FOR GEMCITABINE HCV THERAPY
摘要 A dosage regiment for the treatment of a Flaviviridae infection, including a hepatitis C viral infection, that includes administering gemcitabine (or its salt, prodrug or derivative, as described herein) in a dosage range of approximately 50 mg/m2 per day for between one and seven days (e.g. 1, 2, 3, 4, 5, 6, or 7 days) followed ba cessation of therapy. Viral load is optional ly monitored over time, and after cessation, viral rebound is monitored. Therap y is not resumed unless a significant viral load is again observed, and then therapy for 1-7 days and more preferred, 1, 2 or 3 days is repeated. This therapy can be continued indefinitely to monitor and maintain the health of the patient.
申请公布号 CA2476282(A1) 申请公布日期 2003.08.21
申请号 CA20032476282 申请日期 2003.02.14
申请人 PHARMASSET LTD. 发明人 STUYVER, LIEVEN J.
分类号 C07H19/073;A61K31/7072;A61K45/00;A61P31/14;A61P35/00;C07H19/06;C07H19/16;(IPC1-7):A61K31/505 主分类号 C07H19/073
代理机构 代理人
主权项
地址